Enzyme News and Research

RSS

Inexpensive sleep disorder drug appears to be potent inhibitor of cancer cells

An inexpensive "orphan drug" used to treat sleep disorders appears to be a potent inhibitor of cancer cells, according to a new study led by scientists at Fred Hutchinson Cancer Research Center.

22 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

Combination of vitamin D and BCG vaccine improves bladder cancer survival

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.

22 May 2012

New strategy can reactivate genes that cause cancer tumors to shrink and die

A team of scientists has developed a promising new strategy for "reactivating" genes that cause cancer tumors to shrink and die. The researchers hope that their discovery will aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs.

22 May 2012

Study shows how a drug-lead compound suppresses tumour formation

A team of scientists from the National University of Singapore's (NUS) Department of Biological Sciences and Mechanobiology Institute have discovered how a drug-led compound - a compound that is undergoing preclinical trials as a potential drug - can deprive cancer cells of energy and stop them from growing into a tumour. This drug-led compound is named BPTES.

21 May 2012

HS6ST2 enzyme an important regulator of breast cancer cell-bone interactions

Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a novel mechanism regulating the development of breast cancer bone metastases and showed that heparin-like compounds can potentially be used to inhibit breast cancer metastasis to bone.

21 May 2012

RA drug effective against Entamoeba histolytica

Research by a collaborative group of scientists from UC San Diego School of Medicine, UC San Francisco and Wake Forest School of Medicine has led to identification of an existing drug that is effective against Entamoeba histolytica. This parasite causes amebic dysentery and liver abscesses and results in the death of more than 70,000 people worldwide each year.

21 May 2012

Auranofin effective against amoebas in lab and animal studies

A team of researchers from UCSF and UC San Diego has identified an approved arthritis drug that is effective against amoebas in lab and animal studies, suggesting it could offer a low-dose, low cost treatment for the amoebic infections that cause human dysentery throughout the world.

21 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Quest Diagnostics introduces four new tests panels for CAH

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women.

From Quest Diagnostics 19 May 2012

DCI receives FDA approval for PERTZYE NDA to treat EPI

Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.

19 May 2012

Regular eating times, extended daily fasting may prevent diabetes, obesity

It turns out that when we eat may be as important as what we eat. Scientists at the Salk Institute for Biological Studies have found that regular eating times and extending the daily fasting period may override the adverse health effects of a high-fat diet and prevent obesity, diabetes and liver disease in mice.

18 May 2012

Researchers identify novel base modification in RNA

Over the past decade, research in the field of epigenetics has revealed that chemically modified bases are abundant components of the human genome and has forced us to abandon the notion we've had since high school genetics that DNA consists of only four bases.

18 May 2012

Insight into why diabetics suffer from increased pain and temperature sensitivity

Why diabetics suffer from increased pain and temperature sensitivity is a step closer to being understood and effectively treated.

17 May 2012

Breast cancer cell surface protein blows cover of potent tumor-generating cells

Breast cancer stem cells wear a cell surface protein that is part nametag and part bull's eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation.

17 May 2012

Paper-based diabetes device can be adapted for other applications

With epidemics of Type 2 diabetes looming in rural India, China and other areas of the world where poverty limits the availability of health care, scientists are reporting development of an inexpensive and easy-to-use urine test ideally suited for such areas. The report describing the paper-based device, which also could be adapted for the diagnosis and monitoring of other conditions and the environment, appears in ACS' journal Analytical Chemistry.

17 May 2012